Signaling pathways
-
BA9200 GumelutamideSummary: Gumelutamide is a tetrahydropyridine-pyrimidine compound that acts as an antiandrogenic, antitumor agent. - BA9201 A4B17Summary: A4B17 is a study of androgen-responsive prostate cancer.
- BA9202 VPC-14228Summary: VPC-14228 is a potent inhibitor of the DNA-binding domain of the androgen receptor that interferes with the interaction of the AR with androgen-responsive elements and effectively blocks AR transcriptional activity.
- BA9203 CLP-3094Summary: CLP-3094 is a potent androgen receptor (bindingfunction3) inhibitor.
- BA9204 ARD-2051Summary: ARD-2051 is a potent androgen receptor protein hydrolysis-targeted chimeric degrader with oral activity.
- BA9206 SK33Summary: SK33, an inositol analog, is a potent tissue-selective antiandrogenic active molecule.
- BA9207 N-NitrosodicyclohexylamineSummary: N-Nitrosodicyclohexylamine (NDCHA) is an N-nitroso compound with anti-androgenic activity.
- BA9208 VPC13163Summary: VPC13163 is a potent androgen receptor inhibitor.
- BA9209 TrestoloneSummary: A synthetic androgenic steroid (AAS).
- BA9210 CINPA1Summary: CINPA1 is a potent and specific constitutive androstane inhibitor that does not activate the pregnane X receptor (PXR).